SGLT2 Inhibitor Therapy for Transthyretin Amyloid Cardiomyopathy: Early Tolerance and Clinical Response to Dapagliflozin

Abstract

In tafamidis-treated ATTR-CM patients, initiation of dapagliflozin was well tolerated. The efficacy of SGLT2i therapy in patients with ATTR-CM needs to be studied in randomized controlled trials.